120 related articles for article (PubMed ID: 16018938)
41. Does the tertiary Gleason pattern influence the PSA progression-free interval after retropubic radical prostatectomy for organ-confined prostate cancer?
van Oort IM; Schout BM; Kiemeney LA; Hulsbergen CA; Witjes JA
Eur Urol; 2005 Oct; 48(4):572-6. PubMed ID: 16046051
[TBL] [Abstract][Full Text] [Related]
42. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
43. Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10.
Bastian PJ; Gonzalgo ML; Aronson WJ; Terris MK; Kane CJ; Amling CL; Presti JC; Mangold LA; Humphreys E; Epstein JI; Partin AW; Freedland SJ
Cancer; 2006 Sep; 107(6):1265-72. PubMed ID: 16900523
[TBL] [Abstract][Full Text] [Related]
44. Deferred combined androgen blockade therapy using bicalutamide in patients with hormone-refractory prostate cancer during androgen deprivation monotherapy.
Fujii Y; Kawakami S; Masuda H; Kobayashi T; Hyochi N; Kageyama Y; Kihara K
BJU Int; 2006 Jun; 97(6):1184-9. PubMed ID: 16686709
[TBL] [Abstract][Full Text] [Related]
45. Conformal radiotherapy for detectable PSA following radical prostatectomy: efficacy and predictive factors of recurrence.
Delongchamps NB; Zerbib M; Mejean A; Rouach Y; Debre B; Peyromaure M
Can J Urol; 2009 Oct; 16(5):4813-9. PubMed ID: 19796456
[TBL] [Abstract][Full Text] [Related]
46. Active surveillance with selective delayed intervention for favorable risk prostate cancer.
Klotz L
Urol Oncol; 2006; 24(1):46-50. PubMed ID: 16414494
[TBL] [Abstract][Full Text] [Related]
47. Postradiotherapy 2-year prostate-specific antigen nadir as a predictor of long-term prostate cancer mortality.
Zelefsky MJ; Shi W; Yamada Y; Kollmeier MA; Cox B; Park J; Seshan VE
Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1350-6. PubMed ID: 19515504
[TBL] [Abstract][Full Text] [Related]
48. PSA in the new millennium: a powerful predictor of prostate cancer prognosis and radical prostatectomy outcomes--results from the SEARCH database.
Freedland SJ; Hotaling JM; Fitzsimons NJ; Presti JC; Kane CJ; Terris MK; Aronson WJ; Amling CL
Eur Urol; 2008 Apr; 53(4):758-64; discussion 765-6. PubMed ID: 17868976
[TBL] [Abstract][Full Text] [Related]
49. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
Soga N; Onishi T; Arima K; Sugimura Y
Int J Urol; 2007 Mar; 14(3):192-6; discussion 197. PubMed ID: 17430253
[TBL] [Abstract][Full Text] [Related]
50. Prognostic factors of persistently detectable PSA after radical prostatectomy.
Naselli A; Introini C; Andreatta R; Spina B; Truini M; Puppo P
Int J Urol; 2009 Jan; 16(1):82-6. PubMed ID: 19054168
[TBL] [Abstract][Full Text] [Related]
51. Adjuvant radiotherapy in prostate cancer: predictors of prostate-specific antigen recurrence from the CaPSURE database.
Macdonald OK; D'Amico AV; Sadetsky N; Shrieve DC; Carroll PR
Urology; 2007 Jul; 70(1):106-10. PubMed ID: 17656218
[TBL] [Abstract][Full Text] [Related]
52. Identifying patients at risk for significant versus clinically insignificant postoperative prostate-specific antigen failure.
D'Amico AV; Chen MH; Roehl KA; Catalona WJ
J Clin Oncol; 2005 Aug; 23(22):4975-9. PubMed ID: 16051949
[TBL] [Abstract][Full Text] [Related]
53. Time to detectable metastatic disease in patients with rising prostate-specific antigen values following surgery or radiation therapy.
Slovin SF; Wilton AS; Heller G; Scher HI
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8669-73. PubMed ID: 16361552
[TBL] [Abstract][Full Text] [Related]
54. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
Miyake H; Hara I; Eto H
BJU Int; 2005 Oct; 96(6):791-5. PubMed ID: 16153202
[TBL] [Abstract][Full Text] [Related]
55. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).
Hussain M; Tangen CM; Higano C; Schelhammer PF; Faulkner J; Crawford ED; Wilding G; Akdas A; Small EJ; Donnelly B; MacVicar G; Raghavan D;
J Clin Oncol; 2006 Aug; 24(24):3984-90. PubMed ID: 16921051
[TBL] [Abstract][Full Text] [Related]
56. Long-term prognostic significance of primary Gleason pattern in patients with Gleason score 7 prostate cancer: impact on prostate cancer specific survival.
Tollefson MK; Leibovich BC; Slezak JM; Zincke H; Blute ML
J Urol; 2006 Feb; 175(2):547-51. PubMed ID: 16406993
[TBL] [Abstract][Full Text] [Related]
57. Long-term results and predictive factors of three-dimensional conformal salvage radiotherapy for biochemical relapse after prostatectomy.
Neuhof D; Hentschel T; Bischof M; Sroka-Perez G; Hohenfellner M; Debus J
Int J Radiat Oncol Biol Phys; 2007 Apr; 67(5):1411-7. PubMed ID: 17275204
[TBL] [Abstract][Full Text] [Related]
58. A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy.
Davis NB; Ryan CW; Stadler WM; Vogelzang NJ
BJU Int; 2005 Oct; 96(6):787-90. PubMed ID: 16153201
[TBL] [Abstract][Full Text] [Related]
59. Outcome of prostate cancer patients with initial PSA> or =20 ng/ml undergoing radical prostatectomy.
Zwergel U; Suttmann H; Schroeder T; Siemer S; Wullich B; Kamradt J; Lehmann J; Stoeckle M
Eur Urol; 2007 Oct; 52(4):1058-65. PubMed ID: 17418938
[TBL] [Abstract][Full Text] [Related]
60. PSA kinetics provide improved prediction of survival in metastatic hormone-refractory prostate cancer.
Robinson D; Sandblom G; Johansson R; Garmo H; Aus G; Hedlund PO; Varenhorst E;
Urology; 2008 Oct; 72(4):903-7. PubMed ID: 18639324
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
